title: Benefit and risk of heparin for maintaining peripheral venous catheters in neonates: a placebo-controlled trial.
abstract: OBJECTIVE
  Heparin addition to infusion fluids is used to prolong catheter patency in newborns. Heparin may also induce adverse effects such as bleeding complications and immune-mediated heparin-induced thrombocytopenia (HIT). One objective was peripheral venous catheter patency with heparinization of continuous infusions (0.5 IU/mL). Secondary objectives were incidences of bleeding, clinically manifest HIT, HIT antibodies, and catheter-related complications.
  
  
  METHODS
  Inclusion criteria were anticipated need for intravenous peripheral infusion (>or=5 days for HIT-related endpoints) and postnatal age <28 days at study entry. Exclusion criteria were bodyweight <1000 g, congenital malformation, need for therapeutic anticoagulation or mechanical ventilation, and severe bleeding. HIT antibodies were assessed by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  A total of 145 infants received heparin, and 151 infants received saline. Patient characteristics, number of additional drugs, duration of treatment, and location and size of catheters did not differ. Patency of catheters was 7.4 hours longer in the heparin group (33.8 hours vs 26.4 hours, P<.0001), but the total numbers of catheters did not differ (565 vs 692, P=.3). No infant developed HIT antibodies. Incidences of bleeding complications and thrombocytopenia were comparable between groups.
  
  
  CONCLUSIONS
  Balancing the benefits against the risks of heparin addition and the rare complication of HIT, we will not use 0.5 IU/mL heparin addition to parenteral fluids.
authors.affiliation: Department of Pediatrics, the Institute of Immunology and Transfusion Medicine, and the University Pharmacy, Ernst-Moritz-Arndt University, Greifswald, Germany.
authors.forename: Anne Friederike
authors.initials: AF
authors.lastname: Klenner
authors.forename: Christoph
authors.initials: C
authors.lastname: Fusch
authors.forename: A
authors.initials: A
authors.lastname: Rakow
authors.forename: Ingrid
authors.initials: I
authors.lastname: Kadow
authors.forename: Elke
authors.initials: E
authors.lastname: Beyersdorff
authors.forename: Petra
authors.initials: P
authors.lastname: Eichler
authors.forename: Kathrin
authors.initials: K
authors.lastname: Wander
authors.forename: Theresia
authors.initials: T
authors.lastname: Lietz
authors.forename: Andreas
authors.initials: A
authors.lastname: Greinacher
mesh_terms: D000906:Antibodies / Q000097:blood; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D002406:Catheterization, Peripheral; D002408:Catheters, Indwelling; D003029:Coagulants / Q000037:antagonists & inhibitors; D004311:Double-Blind Method; D004868:Equipment Failure; D005260:Female; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D008297:Male; D010978:Platelet Factor 4 / Q000037:antagonists & inhibitors; D018570:Risk Assessment; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced*
chemical_list: D000906:Antibodies; D000925:Anticoagulants; D003029:Coagulants; D010978:Platelet Factor 4; D006493:Heparin